FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects
Portfolio Pulse from Nina Zdinjak
The FDA has released a report detailing its 50 years of experience with cannabis research, highlighting an increased interest in studying cannabis and cannabis-derived products (CCDPs) as medical treatment options. The FDA is currently reviewing over 150 active investigational new drug applications (INDs) that evaluate CCDPs. The agency has not approved a marketing drug application for cannabis to treat a disease or condition, but it has approved one medicine, Epidiolex, a CBD-based drug for treating severe forms of epilepsy, produced by Jazz Pharmaceuticals. The FDA predicts an increase in INDs evaluating CCDPs.
November 03, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jazz Pharmaceuticals' Epidiolex, a CBD-based drug for treating severe forms of epilepsy, is the only medicine containing a cannabis compound that has been approved by the FDA. The agency's report signals a boost in medical marijuana prospects.
The FDA's report highlights an increased interest in studying CCDPs as medical treatment options, which could potentially lead to more approvals in the future. As Jazz Pharmaceuticals' Epidiolex is currently the only approved medicine containing a cannabis compound, this could potentially boost the company's standing in the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80